Previous 10 | Next 10 |
- Tivozanib Significantly Improves PFS and ORR Compared to Sorafenib and Demonstrates Updated Interim OS HR of 0.99 in Refractory Advanced RCC - - Outcomes Favor Tivozanib in Patients Previously Treated With Checkpoint Inhibitors as Well as Two VEGFR-TKIs - - Data Featured in...
Even though we live in the most technologically advanced times, there are still diseases with ineffective treatments or none at all. This is where up and coming healthcare companies are looking to make it big. The market potential is massive for these companies and it makes them some of the most...
AVEO Pharmaceuticals (NASDAQ: AVEO ): Q3 GAAP EPS of $0.10 beats by $0.07 . Revenue of $25.7M (+940.5% Y/Y) beats by $25.2M . Press Release More news on: AVEO Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ,
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the third quarter ended September 30, 2019 and provided a business update. “This quarter we have made meaningful progress toward our goal of bringing effective and better tolerated therapies to patients battling kidn...
On November 4th, AVEO Oncology ( AVEO ) announced that the FDA "recommended that the Company not submit an NDA at this time" due to FOTIVDA's August interim overall survival "OS" results not alleviating their concerns and "that those results may worsen with final analysis at 263 events, and ...
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the initiation of the CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cytarabine ...
AVEO Pharmaceuticals (NASDAQ: AVEO ) slumps 44% premarket on robust volume in reaction to its update on Fotivda (tivozanib) in patients with highly treatment-resistant renal cell carcinoma (RCC). More news on: AVEO Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the ...
- NDA Filing Planned for 1Q20 for Relapsed/Refractory RCC – - Company Plans Final OS Analysis in 2Q20 - AVEO Oncology (NASDAQ: AVEO) today provided a regulatory update following a meeting with the U.S. Food and Drug Administration (FDA) to discuss results from the August 20...
AVEO Oncology (NASDAQ: AVEO ) says it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating Fotivda (tivozanib),. More news on: AVEO Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
AVEO Oncology (NASDAQ: AVEO) today announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA ® (tivozanib), the Company’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhi...
News, Short Squeeze, Breakout and More Instantly...
AVEO Pharmaceuticals Inc. Company Name:
AVEO Stock Symbol:
NASDAQ Market:
SEOUL, South Korea, Jan. 19, 2023 (GLOBE NEWSWIRE) -- LG Chem, Ltd. (“LG Chem”) (KOSPI: 051910) today announced that it has completed its previously announced acquisition of AVEO Oncology (“AVEO”), a commercial stage, oncology-focused biopharmaceutical company committe...
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, announced that at a special meeting of stockholders ...
BOSTON, Jan. 03, 2023 (GLOBE NEWSWIRE) -- AVEO Oncology (“AVEO”) (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, reminds all AVEO stockholders to vote before AVEO...